M. Howland

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Annals of Oncology.

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Journal of Clinical Oncology.

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

S. Roychowdhury, A. Lamarca, I. Borbath, 2020, Future oncology.

IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.

M. Socinski, M. Nishio, A. Sandler, 2017 .